Telix Pharma Completes Patient Enrollment In Zircon Phase Iii Kidney Cancer Imaging Study
Telix Pharmaceuticals Limited, A Biopharmaceutical Company, Announces That It Has Dosed The Final Patient And Completed Recruitment Into The Phase Iii Pivotal Study Zircon (Zirconium In Renal Cancer Oncology, Nct03849118) Of Its Investigational Renal (Kidney) Cancer Imaging Agent Tlx250-Cdx (89Zr-Dfo-Girentuximab). This Global Study Has Dosed 300 Patients To Date, Exceeding The Target Enrolment Of 252 Patients, Announced On 8 March 2022.Tlx250-Cdx, Which Has Received
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!